Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter, Randomized, Double-Blind, Placebo (Hepatitis E Vaccine) Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant (E.Coli) Human Papillomavirus Bivalent Vaccine in Healthy Women

Trial Profile

A Phase III Multicenter, Randomized, Double-Blind, Placebo (Hepatitis E Vaccine) Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant (E.Coli) Human Papillomavirus Bivalent Vaccine in Healthy Women

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2019

At a glance

  • Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary) ; Recombinant hepatitis E vaccine (Hecolin)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 May 2019 Results of a pre-specified interim analysis, published in the Journal of the National Cancer Institute
    • 17 Jul 2018 Planned End Date changed from 1 Sep 2018 to 28 Feb 2019.
    • 17 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top